I know there is great interest in HSCT and I also know any posts on HSCT is like catnip to the zealots. So I can’t be bothered to engage or defend as no matter what one says it is going to be wrong if is says something that people don’t want to hear. Removing your immune system puts you at serious risk from infection. Once you immune systme regenerates the risk goes away. This is simple immunology 101. What happens with HSCT….So here we have a story from Mexico. There is no conflict of interest reported so I have assume that they are not HSCT doctors who take money for performing HSCT, otherwise it would be like turkeys voting against christmas. You can read the abstract and the conclusions. People 6 months after transplant do OK based on a same numer of infected individuals. If we ask what happens 6 months after alemtuzumab I am sure we would get the same answer.
Olivares Gazca JC, Gómez Almaguer D, Gale RP, Ruiz Argüelles GJ. Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis. Hematology. 2020; 25:320. doi: 10.1080/16078454.2020.1802931.
The pandemic of coronavirus infectious disease-2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a threat to global health. During the pandemic changes in how haematopoietic cell transplant are done are suggested such as avoiding the use of immunosuppressive drugs. From June 2015 to March 2020, we autografted 894 persons with multiple sclerosis (MS) using a conditioning regimen of cyclophosphamide (200 mg/kg (and rituximab (1 g). The first case of COVID-19 in México was diagnosed on 28 February 2020. To determine any interaction between SARS-CoV-2-infection and our program, we studied 13 subjects autografted 2–27 March 2020 during the initial part of the pandemic in México who had negative results of qualitative reverse transcription–polymerase chain reaction (qRT-PCR) tests for SARS-CoV-2 before and after their transplant. We also sent a questionnaire to 894 consecutive transplant recipients, 330 (37%) of whom responded. Four subjects indicated they were infected with the SARS-CoV-2 and developed COVID-19, 6–31 months post-transplant, only 1 of whom was hospitalized for 2 days, not in an intensive care unit. None were treated for COVID-19. Our data suggest, but do not prove, a low risk of developing COVID-19 in autotransplant recipients with MS. We cannot comment on the risk of SARS-CoV-2-infection as most respondents were not tested by qRT-PCR or for anti-SARS-CoV-2 antibodies. Also, there may be a selection bias of respondents.
No potential conflict of interest was reported by the author(s).